[Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain
Farmacia Hospitalaria · 2025
DOI: 10.1016/j.farma.2025.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Antonio García-Quintana und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Cardiología, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain. Hauptthemen laut MEDLINE: Heart Failure, Aminobutyrates, Tetrazoles, Angiotensin Receptor Antagonists. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Farmacéutica.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
INTRODUCTION: Heart failure is an increasingly common syndrome with a rising prevalence, which associates significant costs, mainly related to hospitalization. In fact, heart failure is the most frequent diagnosis in hospital discharges in Spain. OBJECTIVE: To analyze the economic impact of new treatments for heart failure with reduced ejection fraction such as sacubitril/valsartan in out-patient and in-patient setting. MATERIAL AND METHODS: The present economic evaluation study was carried out by developing a Markov model. Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator. Total costs, years of life gained, quality-adjusted life years, and incremental cost-effectiveness ratio and incremental cost-utility ratio were analyzed. Data were obtained from the PARADIGM-HF and PIONEER-HF studies. RESULTS: The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved. CONCLUSION: This study shows that starting sacubitril/valsartan from hospital admission for heart failure is cost-effective from the perspective of the National Health Service in Spain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Cardiología, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
- Servicio de Farmacia, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
- Early Products and Health Economics and Outcomes Research, Novartis Farmacéutica, Madrid, Spain. Electronic address: javier.parrondo@novartis.com.
Förderung
- Novartis Farmacéutica
Zitieren
APA
García-Quintana, A., Alonso Ramos, H., & Parrondo, J. (2025). [Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2025.08.004
Vancouver
García-Quintana A, Alonso Ramos H, Parrondo J. [Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2025.08.004
BibTeX
@article{GarcaQuintana2025,
author = {García-Quintana, Antonio and Alonso Ramos, Héctor and Parrondo, Javier},
title = {[Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain},
journal = {Farmacia Hospitalaria},
year = {2025},
doi = {10.1016/j.farma.2025.08.004}
}
EUVIMED